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Advances in omics and specifically genomic technologies are increasingly transforming
rare disease diagnosis. However, the benefits of these advances are disproportionately
experienced within and between populations, with Indigenous populations frequently
experiencing diagnostic and therapeutic inequities. The International Rare Disease
Research Consortium (IRDiRC) multi-stakeholder partnership has been advancing
toward the vision of all people living with a rare disease receiving an accurate diagnosis,
care, and available therapy within 1 year of coming to medical attention. In order to
further progress toward this vision, IRDiRC has created a taskforce to explore the access
barriers to diagnosis of rare genetic diseases faced by Indigenous peoples, with a view of
developing recommendations to overcome them. Herein, we provide an overview of the
state of play of current barriers and considerations identified by the taskforce, to further
stimulate awareness of these issues and the passage toward solutions. We focus on
analyzing barriers to accessing genetic services, participating in genomic research, and
other aspects such as concerns about data sharing, the handling of biospecimens, and
the importance of capacity building.
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INTRODUCTION
The number of people worldwide living with a rare disease
is estimated between 263 and 446 million (1), and there
are an estimated 370–500 million Indigenous peoples in the
world, spread across 90 countries and speaking the major
share of the world’s almost 7,000 languages (2). People with
rare diseases frequently suffer from inequitable access to
diagnosis and treatment, and the majority of the world’s
population is currently outside the perimeter of readily accessible
diagnostic applications.
Indigenous peoples represent a rich diversity of cultures,
religions, traditions, languages, and histories. Globally, the health
status of Indigenous peoples frequently varies significantly from
that of non-Indigenous people population. While making up
<5% of the world’s population, Indigenous people account for
15% of the poorest (3). Indigenous people life expectancy is up
to 20 years lower than that of the non-Indigenous population
(3). Children born into Indigenous families often live in remote
areas where there may be relative underinvestment in, or access
to, basic social and medical services. Indigenous families, be
they metropolitan or more remote, may have limited or no
access to culturally appropriate care, due to linguistic, geographic,
financial, and other factors.
It takes an average of 5 years to diagnose a child with a rare
disease (4). Given known inequities in Indigenous health care,
and clinical experience of rare disease diagnosis in Indigenous
families (5), the diagnostic odyssey is even more challenging
for Indigenous persons living with rare diseases, and there is a
need for research assessing the impact of this on the Indigenous
communities. These delays often severely limit the benefits
of an accurate diagnosis for Indigenous peoples, including
psychological relief, reduced isolation, reduction of unnecessary
investigations, access to improved or best practice medical care,
genetic counseling, clarification of recurrence risk, provision of
additional reproductive options, and in some cases access to
social and educational services (6).
Over the last 20 years, Indigenous people’s rights have been
increasingly recognized through the adoption of international
instruments and mechanisms, such as the United Nations
Declaration on the Rights of Indigenous Peoples (UNDRIP) in
2007 (7), the American Declaration on the Rights of Indigenous
Peoples in 2016, 23 ratifications of the Indigenous and Tribal
Peoples Convention from 1991, the establishment of the United
Nations Permanent Forum on Indigenous Issues (UNPFII),
the Expert Mechanism on the Rights of Indigenous Peoples
(EMRIP), and the UN Special Rapporteur on the Rights of
Indigenous Peoples (UNSR) (8). There is also an increasing
awareness and formal recognition of the human rights of
people living with rare, including undiagnosed, diseases (9).
Collectively, these factors provide a convergent tapestry of rights
and recognition to support advancing rare diseases diagnosis for
Indigenous people.
Significant diagnostic delays and inequitable access to
diagnostic services for people living with a rare disease has
prompted a response by initiatives at local, national, and
international levels. By way of just one example, the US
National Institutes of Health (NIH) established in 2008 the
Undiagnosed Diseases Program (UDP) (10), and subsequently,
the Undiagnosed Disease Network (UDN; https://undiagnosed.
hms.harvard.edu), and similar programs were established
globally by countries participating in the Undiagnosed Diseases
Network International (UDNI; http://www.udninternational.
org) (11). Such programs are advancing the integration
of genomics and other “omics” technologies into medical
practice to reduce diagnostic delays and improving patient
and family journeys. Increasing equity, including that for
Indigenous peoples, is a key consideration for this and other
diagnostic initiatives.
Increased diagnostic certainty may be provided through
various means such as clinical expert opinion and clinical
consensus including with application of diagnostic criteria where
they exist (for both genetic and non-genetic rare diseases);
through other phenotypic approaches such as facial analysis and
other imaging; and through the building of Indigenous genomic
databases and the identification of rare pathogenic variants
in Indigenous Peoples with a suspected rare genetic disorder,
or other “omics” technologies (e.g., epigenetic signatures). The
International Rare Disease Research Consortium (IRDiRC; www.
irdirc.org) has set the goal of enabling all people living with
a rare disease to receive an accurate diagnosis within 1 year
of coming to medical attention (12). However, significant
barriers remain regarding access to diagnosis for Indigenous
populations, including but not limited to poorer access to
(gen)omic technologies and the research that drives them,
which prevent Indigenous peoples from receiving appropriate
benefits from (gen)omic and other new knowledge. Hence,
IRDiRC has formed a taskforce to identify the barriers for the
diagnosis of rare genetic diseases in Indigenous peoples, and
areas in which there are opportunities for improvement. This is
adding to the knowledge base informing future development of
recommendations for improving diagnosis of genetic and rare
diseases for Indigenous peoples. In this article, we focus our
analysis specifically on the limited access to diagnostic services
and clinical expertise, underrepresentation in genomic databases
and genomics research in general, concerns with the handling
of biospecimens, data use and data sharing, and the importance
of building capacity within communities. We provide some
examples of initiatives addressing these barriers, which are briefly
summarized in Table 1.
Access to Clinical Genetic Services
Clinical genetic service providers are at the front line for
rare disease diagnostics and frequently act as the portal to
and from translational research. Indigenous access challenges
to these services, and associated testing, can include lack of
referral and/or referral bias, location, cost, availability, and
cultural appropriateness. This includes culturally appropriate
education materials that resonate with Indigenous narratives
and incorporate indigenous language; meeting places and
clinical processes that accommodate for familial and community
participation; consent processes adaptable to family structures;
involvement of culturally appropriate support and liaison
persons for addressing racism and discrimination; and cultural








































TABLE 1 | Initiatives to improve Indigenous access to genetic and genomic research and health care.
Initiative Country Description Area
Lyfe Languages (38) Australia Initiative to translate the standardized description of phenotypic
abnormality in man (the Human Phenotype Ontology) into
Indigenous languages.
Indigenous languages initiative
Better Indigenous Genetics (BIG) Health Services project (42) Australia National partnership project that aims to improve the provision of
clinical genetic services to Aboriginal and Torres Strait Islander
people.
Indigenous clinical genetic service
National Center For Indigenous Genomics (48) Australia Body within the Australian National University (ANU) dedicated to
bringing the benefits of genomic medicine to Indigenous
Australians by creating Indigenous genomic data resources.
Indigenous genomics database
Silent Genomes (49) Canada Precision medicine project which aims to create a database of
background genetic variations for Indigenous populations living in
Canada and globally.
Indigenous genomics database
Aotearoa Variome (51) New Zealand The Aotearoa Variome project will assemble genomic resources
and develop a catalog of genetic variants present in the genomes
of New Zealanders.
Indigenous genomics database
A Framework for Enhancing Ethical Genomic Research with
Indigenous Communities (60)
International Ethical framework informed by community-based participatory
research (CBPR) principles, to engage Indigenous people and
communities in genomic research.
Indigenous ethical frameworks
Te Mata Ira: Guidelines for Genomic Research with Maori (61) New Zealand It outlines a framework for addressing Māori ethical issues within
the context of genetic or genomic research.
Indigenous ethical frameworks
He Tangata Kei Tua: Guidelines for Biobanking with Maori (62) New Zealand It describes a model for biobanks to guide culturally informed
governance, operational, and community engagement activities.
Indigenous ethical frameworks
Ethical Conduct in Research with Aboriginal and Torres Strait
Islander Peoples and Communities (69)
Australia It provides values and principles to ensure that research
conducted with or for Aboriginal and Torres Strait Islander people
and communities, or their data or biological samples, is ethically
conducted.
Indigenous ethical frameworks
Guidelines for Genomic Research with Aboriginal and Torres
Strait Islander Peoples of Queensland (70)
Australia (Queensland) Guidelines for researchers on how to engage and partner with
Queensland communities for potential genomic-research projects.
Indigenous research guideline
Tri-Council Policy Statement 2: Ethical Conduct for Research
Involving Humans (TCPS2) (71)
Canada Chapter 9 outlines a framework for the ethical conduct of research
involving Indigenous peoples.
Indigenous research guideline
Maori Data Sovereignty Network (Te Mana Raraunga) (79) New Zealand National-level Indigenous data sovereignty network. These
networks are creating principles for Indigenous data sovereignty
and Indigenous data governance to inform the appropriate
management and sharing of data.
Indigenous data network
United States Indigenous Data Sovereignty Network (80) United States National-level Indigenous data sovereignty network. Indigenous data network
Maiam nayri Wingara Aboriginal and Torres Strait Islander
Data Sovereignty Collective (81)
Australia National-level Indigenous data sovereignty network. Indigenous data network
Research Data Alliance International Indigenous Data
Sovereignty Interest Group (82)
International Interest Group focus on building an international Indigenous Data
Sovereignty research platform.
Indigenous data infrastructure
Global Indigenous Data Alliance (83) International International Indigenous Data Sovereignty Network advocating for
rights and interests to data.
Indigenous data alliance
Care Principles of Indigenous Data Governance (84) International International framework for ethical use of Indigenous data. Indigenous data framework
Genetic Education for Native Americans (89) United States Native-specific educational program on genetics. Indigenous education
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competency among genetic health-care staff and capacity
building in genetic and rare diseases (be they genetic or
environmental) in the primary care workforce. Each of
these issues affects engagement in, and delivery of, rare
disease diagnosis.
The total burden of rare diseases in Indigenous
communities is unknown. Estimates of prevalence of rare
disease in “mainstream” (i.e., predominantly non-indigenous
ethnicity/ancestry) communities from the Orphanet database
range from 3.5 to 5.9%, of which 71.9% have a hereditary basis
(1). Assuming similar prevalence in Indigenous communities,
this equates to 12–20 million indigenous people worldwide
affected by at least one rare disease, based on an estimated
worldwide population of 476 million indigenous peoples (8).
While many Indigenous people live in metropolitan areas,
some Indigenous groups are remote or nomadic with limited
geographic access to genetic health care services—and therefore
to a rare disease diagnosis. As an example, approximately 1 in
5 Indigenous Australians (Aboriginal and Torres Strait Islander
peoples) live in remote areas and about 1 in 3 live in major cities
(13). In Canada, half of Indigenous peoples (First Nations, Inuit,
and Métis) live in a rural environment (14). For less developed
populations globally, even though a doubling of urbanization
occurred over the past 50 years, ∼1 in 2 people still live in rural
areas (15). Telehealth and outreach clinics are undoubtedly an
important part of the matrix of approaches to accommodate
geographic access issues. Moreover, there are other challenges
for Indigenous families, in terms of technology, internet access,
bandwidth, reliability, and cultural appropriateness. In the
African context, the needs of people living with rare diseases
must also be balanced with basic needs, such as nutrition and
communicable-disease prevention (16).
While many rare diseases affect Indigenous populations at
similar rates to non-indigenous peoples, some rare diseases
are geographically and/or culturally concentrated and this
has implications for tailoring research and clinical care. An
example is that the Machado-Joseph disease (MJD)—also called
spinocerebellar ataxia Type 3 (SCA3)—is estimated to be more
prevalent among Aboriginal people from small communities
in remote northern Australia than anywhere else in the world
(17). Geographical isolation and cultural preference for large,
closely tied families have resulted in disproportionately high
numbers of people living with this condition. Currently, over 650
Aboriginal Australians are thought to be “at-risk” of developing
the disease. The Australian MJD Foundation (MJDF; https://
mjd.org.au) was established in 2008, as a community driven
response to families affected by MJD, and has pioneered an
innovative model of disability service delivery to meet the
needs of Aboriginal communities in remote Northern Australia
(17). Core to its principles is the implementation of a “two-
way,” bicultural working model, i.e., the services are delivered
in community by an Aboriginal community worker and a
non-Aboriginal health or community service professional. The
approach allows first language support which minimizes the
potential for misunderstanding and disengagement for cultural
mistakes. Another example from Canada is work with Gitxsan
Health Society to identify the cause of sudden death, often at a
young age, in this First Nation’s community in northern British
Columbia (18, 19). This resulted in the discovery of a mutation in
the KCNQ1 gene, which causes the Long QT syndrome and has
now been found in ∼1.5% of the community’s population. The
team worked with the community to ensure that the research was
performed in a culturally safe manner. Long QT syndrome is a
rare heart rhythm condition which can be lethal if left untreated,
but with appropriate treatment and monitoring patients can live
a normal life. Today, anyone with a predisposition to Long QT
syndrome receives evidence-based care by a team of northern
British Columbia health-care workers supported by the British
Columbia Inherited Arrhythmia Program. An African example
is glutaric aciduria type 1 (GA1), a rare disease that can be
detected by newborn screening and is treatable. The Black South
African population, including Indigenous (San and KhoeKhoe)
and non-Indigenous peoples, has a predicted prevalence of this
disorder that is 20 times higher (1:5184) than global average
(1:100,000) (20).
Understanding the total burden of rare diseases in Indigenous
populations within the country they reside, the identification of
the actual conditions themselves and their individual prevalence
and community distribution are significant knowledge gaps to be
addressed in terms of tailoring access, and provision of, genetic
health care. In addition to diagnostic and epidemiological
initiatives, rare disease codification with granular and
interoperable systems, such as Orphanet coding (21), in
health data sets will be critical, as well as documentation therein
of Indigenous status.
Financial access issues are also critical; these may be of
particular relevance since poverty is more common among
Indigenous, compared to non-Indigenous, people. Also, it is
important that funding/reimbursement is sufficient to cover all
aspects of diagnostic care, such as pretest and posttest culturally
appropriate counseling—and not just the cost of a genetic test.
Given that Indigenous people are more likely to live regionally
or remotely when compared to non-Indigenous people, methods
to improve access to testing, service, and research will require a
combination of approaches that embrace a mixture of telehealth,
local capacity building, and outreach models. Approaches that
map access closer to home and incorporate cultural, geographic,
weather, and language factors will also be beneficial (e.g.,
Mappa; https://mappanews.org.au).
Poor access to clinical expertise at the point of care and lack of
referrals (or referral bias) to genetics specialists is another barrier
to diagnosis. Given the diversity and rarity of these disorders,
diagnosis of rare diseases is often difficult. Rare in presentation,
they can sometimes go unrecognized by practitioners. Moreover,
expertise and specialist knowledge may be scarce (22). The
development of the European Reference Networks (ERNs) by
the European Commission in 2017 was a priority action to
compensate for the scarcity of knowledge on rare diseases
and improve access to clinical expertise across Europe (23).
Preliminary data from the Australian Northern Territory Genetic
Service suggested that rates of referral for Indigenous patients
were less than half of what would be expected based on the
population (24). This may be due to general lack of awareness
of indicators of rare diseases by referring doctors, attributing
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symptoms to other more common disorders, or a belief that
services are not accessible or will not be attended.
Recognizing a patient with a rare disease can be particularly
challenging in remote areas where expertise in rare diseases does
not exist and for ethnic minorities such as the Irish Traveler
population, a distinct Irish ethnic minority. The Irish Travelers
are an endogamous nomadic ethnic minority group with a very
high incidence of rare diseases. As they practice inter-cousin
marriage, a greater incidence of autosomal recessive genetic
disorders is reported with many rare diseases occurring in this
population with a prevalence threshold >5 in 10,000 (25–27).
Clinicians who are less familiar with this population had until
recently no resources to support more timely diagnosis of the
rare disorders in Irish Traveler patients. A catalog of the disease
mutations of known genetic disorders found among this ethnic
group is now publicly available (26), and a database of genetic
disorders for Irish Traveler is under development to facilitate
diagnosis at the point of care (27). National and ethnic specific
mutation databases that may be used, for example, to facilitate
the provision of genetic services, have been developed for a
number of populations worldwide. Some examples include the
Mediterranean Founder Mutation Database (28), the Omani
National Genetic Database (29), the Israeli National Genetic
Database (30), the Moroccan Genetic Disorders Database (31),
and the Amish, Mennonite, and Hutterite Genetic Disorder
Database (32).
A lack of cultural appropriateness may also challenge
Indigenous rare disease diagnosis. This may be due to language
barriers, location and setup of clinical rooms, a lack of accounting
for gender roles and responsibilities, or lack of awareness of other
cultural norms and responsibilities. Communication between
Indigenous patients and health-care practitioners’ professionals
continues to be problematic and is arguably the greatest barrier
to the delivery of successful health care and translational
research for Indigenous peoples (33). Communication barriers
include language issues and the use of medical jargon. These
undermine constructive practitioner–patient relationships and
result in Indigenous patients and families feeling alienated, non-
compliant, and disengaged from health care. Indigenous patients
and families want to be informed about health and disease,
while information is frequently lacking, inadequate, or presented
in ways that are incongruent with indigenous peoples’ beliefs,
narratives, and experiences (34, 35). Communication issues are
compounded when families are uninvolved in communication
processes (36, 37). Additionally, a history of negative health-care
experiences that parallel other negative colonization experiences
results in mistrust and suspicion by Indigenous people of health
practitioners and patient information provided (36). Building
trust through sustained community partnerships and the use
of culturally appropriate language and concepts are critical.
One initiative to build the lexicon, narratives and trust to
address rare diseases communication issues is Lyfe Languages
(www.lyfelanguages.com) (38), which involves translating the
standardized description of phenotypic abnormality in man
(the Human Phenotype Ontology) into Indigenous languages
through community and transgenerational partnerships.
Launched with a focus on Aboriginal Australian languages, this
has now extended to African and Swedish (Sami) languages.
Where Indigenous people may be fluent in English, have English
as a second, third, or fourth language, or speak a blended mixture
of English and Indigenous languages, such as Aboriginal-English
for example, outputs of Lyfe Languages have been adapted to
these contexts. Recognizing that some Indigenous people may
have no or intermittent internet access, Lyfe Languages has
commenced the development of resources (e.g., Apps) that are
variably web-based or mobile applications and designed to run
with periodic syncing to a web platform, while also supporting
scalable and bespoke hard copy (paper) resource development.
While there is a relative dearth of initiatives to improve
Indigenous access to genetic and genomic care, from a non-
disease-specific basis and an Australian perspective, over the
last decade, a number of state-based, multi-state, and more
recently national approaches in Australia have begun to address
inequitable access to genetic diagnostics and genetic health care
across the breadth of rare diseases. These both complement
and learn from the extensive work of the MJD Foundation in
Australia’s Northern Territory. They include initiatives from The
National Center for Indigenous Genomics (described further
below); the work of the Western Australia (WA) Health
Department, the Aboriginal Health Council of WA, and WA
Aboriginal Communities (39), ACTG—Aboriginal Community-
led Translation of Genomics (40); the work of Genetic Health
Queensland and Queensland Aboriginal and Torres Strait
Islander Controlled Health Services (41); the Better Indigenous
Genetics (BIG) Project, a translational research project for
improving genetic health care service delivery in Australia (42);
andmore recently the work of the POCHECenter for Indigenous
Health (43). Each has specific foci and overlaps.
Underrepresentation in Genomic Research
and Reference Databases
The emergence of large-scale databases and biobanks, prompted
by the proliferation of large-scale population genomics
projects worldwide, has paved the way to genomic medicine.
Globally, however, Indigenous peoples remain understudied
and underrepresented in genome reference databases (44). For
example, a recent analysis revealed that as of 2018, only 22%
of individuals in genome-wide association studies (GWAS)
were of non-European ancestry (45). People of African and
Latin American descent and Indigenous people combined
represented <4% of participants. Indigenous participants
represented 0.02%, which equates to an alarming 250-fold
underrepresentation based on the number of Indigenous people.
This under-representation of ethnically diverse populations
in human genomic studies has important implications for the
interpretability of genomic variants and diagnostic assessments
(46). As genome sequencing is increasingly used in the diagnosis
of rare and undiagnosed conditions (47), reference genomes
from more ethnically diverse populations are needed for
reliable interpretation of results and ultimately the effective and
responsible implementation of precision medicine in minority
populations (16, 46).
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A number of initiatives are seeking to address the gap in
the availability of Indigenous genome reference databases and
ensure culturally appropriate access to data by engaging and co-
designing with Indigenous communities, ascertaining the data
through trusted partnerships and making it available through
mechanisms that embrace both FAIR and CARE principles,
discussed further in section Cultural Considerations for the
Use of Biospecimens and Data Sharing. The National Center
for Indigenous Genomics (NCIG, https://ncig.anu.edu.au) is
creating Australia’s first database of Indigenous genomes for
use in research of benefit to Indigenous Australians (48).
The resource is being developed from an existing collection
of Indigenous biospecimens held by the Australian National
University (ANU) since the 1960s and supplemented by the
ongoing addition of new material. Another Australian initiative
includes the work of the Telethon Kids Institute to deliver the
first whole-exome genomic reference data, and related data access
processes, initiating with Western Desert People of Western
Australia (40). In Canada, the Silent Genomes project launched
in 2018 with the goals of reducing health-care disparities
and improving diagnostic success for Indigenous children
with genetic diseases plans the development of a database
of background genetic variations for Indigenous populations
from across Canada (49, 50). In Aotearoa/New Zealand, a
similar initiative has commenced, with the goal of developing a
catalog of genetic variants within Indigenous Māori, to expedite
identification of causative variants and disease diagnoses, as well
as development of gene-based diagnostics (51). Like the Silent
Genomes project, this is co-led by Indigenous researchers and
guided by Indigenous ethical frameworks relevant to the study
populations (50).
Other efforts to include minority populations in human
genetic studies include the Human Heredity and Health in
Africa Initiative (H3Africa; https://h3africa.org), jointly funded
by the NIH in the US and the Wellcome Trust in the UK to
advance African-led genome research (52), the UK MRC-funded
International Center for Genomic Medicine in Neuromuscular
Diseases (ICGNMD) (53), and the NIH All of Us research
program (https://allofus.nih.gov), a precision medicine initiative
which plans to collect DNA and health data from one million
people including American Indians and Alaska Natives (54).
China has also launched the precision medicine initiative (55),
supporting the cohort studies covering healthy population and
special disease populations in different geographical areas, where
the ratio of Han ethnicity and minority peoples varies among
each other. One of the cohort studies with the funding from the
precision medicine initiative, covering the registry for over 100
rare diseases, has been performed since 2016 and it recruited
patients with a breadth of ethnicities in China (56).
However, aiming for amore diverse population representation
in genomic research is not without challenges. In the US, for
example, while efforts to recruit tribal nations in the All of
Us cohort study are ongoing, a recent report from the Tribal
Collaboration Working Group has underlined a range of issues
that need to be addressed if tribes are to participate, including
a need to recognize tribal sovereignty, rights, and interests (57).
The report also raised questions about responsible data use,
cultural appropriateness, biospecimen storage and access, and
protection and benefits. In another study examining Indigenous
Canadians’ concerns for contributing their data to a genomic
database, issues were raised around lack of trust due to historical
transgressions, control and ownership of samples, privacy, and
fear of discrimination (58).
Whereas experiences with unethical research practices have
caused some individuals to mistrust health research and resulted
in Indigenous peoples’ hesitancy to participate in genomic
research (59), guidelines and ethical frameworks for respectfully
engaging with Indigenous communities have emerged in recent
years to help build trust and repair relationship. Guidelines
for genomics research with Indigenous peoples developed by
countries such as the US, Canada, New Zealand, and Australia
now provide broad protections for research participants,
including protection for sample collection, secondary uses,
benefits, and the right to withdrawal from research (59).
A framework for enhancing ethical genomic research with
Indigenous communities provides a set of principles for
conducting respectful engagement, such as understanding
tribal sovereignty and research regulation, engaging with the
community throughout the research process, building cultural
competency of researchers, improving transparency of research
practices, building tribal capacity in the research process,
and disseminating research findings in a community-accessible
format (60). Additionally, the development of culturally
appropriate guidelines such as Te Mata Ira: Guidelines for
Genomic Research with Maori in New Zealand (61) provides
directions on the cultural concepts, logic, and values that
underpin Maori perspectives on genomic research and outlines
a framework to engage communities in a culturally acceptable
manner. A culturally informed biobank model that draws on
Maori-informed practices has also been developed and provides
a framework for considering cultural values in relation to
Indigenous peoples in other countries, and society in general,
to ensure that biobanking policies, procedures, and practices are
culturally acceptable (62).
Cultural Considerations for the Use of
Biospecimens and Data Sharing
Indigenous cultural practices add complexity to the ethical
issues surrounding genetic and genomic research, at both
the individual and collective levels. Challenges to incorporate
local cultural practices into research may negatively influence
decisions about participation in a research project (63–65). For
instance, indigenous perceptions that blood specimens and other
tissue samples remain intimately connected to their ancestors
and their lands raise ethical concerns related to the collection,
storage, and use of biospecimens (63, 65). It also raises questions
about collective ownership, tribal belonging, repatriation, and
the use of biospecimens beyond national borders (63). In
Australia, the NCIG addresses these challenges by including
an Indigenous Majority Board on its governance, which is
responsible for the custodianship of biological samples and for
its management and use (66). Recently, the NCIG started to offer
participants and relatives of deceased people whose historical
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samples are in its collection the option of having their remains
repatriated to their place of origin (67). Research approaches
that promote community participation, such as the application of
community-based participatory research (CBPR) principles (68),
the adoption of ethical research guidelines (61, 62, 69, 70), and the
development of culturally informed policies (71, 72) offer ways to
ensure that research involving indigenous peoples is premised on
respectful relationships.
Indigenous concerns around data use and sharing is another
barrier to research participation (73, 74). This is increasingly
important as the current move toward broad data sharing and
open data impacts the data governance rights of Indigenous
nations (75). As a response, stricter mechanisms of control
over biological samples and associated data are emerging
by Indigenous Peoples’ (e.g., tribal review/oversight boards,
research codes, policies), and a global call for “Indigenous data
sovereignty”—the right of Indigenous peoples and tribes to
govern the collection, ownership, and application of their own
data—is growing in intensity and scope (75, 76). Yet, at the
same time, it was also acknowledged that stricter mechanisms of
control to protect Indigenous rights may deepen the “genomic
divide” by excluding them from the potential benefits of data
sharing (77). This is especially relevant to rare diseases, where
knowledge and expertise are limited and patient populations are
geographically dispersed (78). Disparate data is a key barrier
to detect rare diseases and the sharing of genomic and clinical
data across country borders is imperative to help accelerate
the time it takes to diagnose a rare disease. A counterpoint is
that solutions that accommodate Indigenous concerns over data
management and sovereignty and, through that build trust, may
ultimately facilitate the scaling of data sharing for Indigenous and
non-Indigenous people.
The reclaiming of Indigenous data sovereignty (IDS) entails
Indigenous people being in control of their data and comprises
the entitlement to Indigenous data governance (75). As the
first Indigenous-governed genome facility in the world, the
NCIG in Australia gives control of decision-making back to
Indigenous people (66). The Canadian’s Silent Genomes is also
working in concert with Indigenous Canadian organizations
and communities to establish processes for Indigenous-led
governance of biological samples and genomic data (49).
Additionally, growing IDS networks are working to shape
open data principles to better respect the rights of Indigenous
peoples, e.g., the establishment of national Data Sovereignty
networks in New Zealand (Te Mana Raraunga; https://
www.temanararaunga.maori.nz) (79), US (USIDSN; https://
usindigenousdata.org) (80), and Australia (MaiamnayriWingara;
https://www.maiamnayriwingara.org) (81); the International
Indigenous Data Sovereignty Interest Group at the Research Data
Alliance (RDA IDS Group; rd-alliance.org) (82); and the Global
Indigenous Data Alliance (GIDA; https://www.gida-global.org)
(83). Released under the auspices of RDA, the CARE Principles
of Indigenous Data Governance (collective benefit, authority
to control, responsibility, ethics) provide the first international
framework for the ethical use of Indigenous data (84). The
Principles reflect the crucial role of data sharing and complement
the existing FAIR (Findable, Accessible, Interoperable, Reusable)
principles (85) as a key principle guiding equity and ethics in data
open movements.
The need for phenotypic reference data parallels the need
for genomic reference data (86). This will require dedicated
initiatives for instance for imaging data, such as (3D) facial
analysis (87) that can accommodate the same considerations as
for (gen)omic data.
Capacity Building and Empowerment
Engagement and consultation with community members, respect
for cultural differences, and transparency around research are
key elements for ethical research involving Indigenous peoples
(60). These are seen as important steps toward forming research
relationships built on trust, respect, and mutual interests,
which in turn can enhance research participation. To this
end, it is critically important to increase capacity among
Indigenous and non-Indigenous peoples alike. Ensuring that
non-Indigenous researchers have adequate cultural competency
to engage with Indigenous communities in a research project
often requires training before its onset. Funding bodies, such as
the Australia’s National Health and Medical Research Council
(NHMRC) and Human Research Ethics Committees (HRECs),
require researchers to demonstrate capacity to effectively conduct
research with Aboriginal and Torres Strait Islander peoples (70).
Recently, Silent Genomes published a document to support and
foster cultural safety practices among genetic counselors working
with Indigenous families (88). It is also currently developing
educational materials to increase communities’ genetic literacy
(49). Promoting genomic literacy among Indigenous people and
communities is an important area to enhance informed decision-
making. The Genetic Education for Native Americans (GENA)
pioneered such efforts by offering Native Americans workshops
on genetics at national conferences. Today, GENA has developed
into an educational program to Native Americans on genetic
science (89). Although not targeted to Indigenous peoples, the
NIH National Human Genome Research Institute (NHGRI;
https://www.genome.gov) has developed tools and provides a list
of useful educational resources to advance genomic literacy for
the general public (90).
The current and projected shortage of medical geneticists and
genetic counselors, who historically have provided the majority
of genetic services, has created a need for genomic education
of health-care professionals across disciplines (91, 92). The
African Genomic Medicine Training (AGMT) Initiative, for
example, was established to develop knowledge and skills of
non-specialist providers in genomic medicine (93). Indigenous
people, especially those living in rural and remote areas, have
poor access to health services (94) and little to no access to
genetic health services. An important aspect for addressing
racial and ethnic health-care disparities and improving access
to genetic services for underserved patients, and cross-cultural
communication, is ensuring a more diverse genetic workforce
(95). In a recent survey on the demographics of certified Genetic
Counselors in the US, 90% of respondents identified themselves
as Caucasian, while only 1% of respondents identified as black
or African American. Just over 2% of respondents identified
as Hispanic, 0.4% identified as American Indian or Alaskan
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Native (96). When compared to the racial/ethnic distribution
in medical education and the health-care workforce, Black or
African American and American Indian or Alaska Natives are
also underrepresented (97). The Minority Genetic Professionals
Network (https://minoritygenetics.org) was formed in 2018 as
an initial step to develop a more diverse workforce of medical
genetic professionals to meet the needs of racial and ethnic
minority populations (98). In Australia, the Better Indigenous
Genetics (BIG) Project will develop training courses targeted to
build capacity of Aboriginal health care workers to collaborate
in the provision of genetic health service and primary care for
Indigenous people. Songlines and weaving are an educational
initiative being developed as a partnership between the Western
Australian Register of Developmental Anomalies, Genetic
Services of Western Australia, and the Roy Hill Community
Foundation to develop culturally appropriate, culturally
endorsed, and culturally resonant education information for
use in clinical genetic practice (99). The first educational
product uses the Aboriginal Song Line narrative to explain
basic concepts of genetics, inheritance, and genetic health care.
Capacity building in Indigenous rare diseases policy will also
be required.
The dynamics of the lack of racial and ethnic diversity
in genomics is paralleled in the US science and engineering
workforce as according to the most recent data, American
Indians or Alaska Natives are underrepresented as are blacks and
Hispanics relative to their presence in the overall US workforce
(100). Diversification of the research workforce is one way to
ensure that genomic research better serves the needs of diverse
and under-represented communities (101). Furthermore, the
inclusion of Indigenous researchers in genomics can bring
greater transparency to the research process, facilitate the
dialogue between researchers/universities and Indigenous
communities, and foster the development of research skills in
genomics within communities, thereby strengthening inclusivity
in biomedical research (60, 102). The Summer internship
for Indigenous peoples in Genomics (SING; https://www.
singconsortium.org) program offers a successful model for
training and retaining Indigenous researchers in genomics.
Launched first in the US and further expanded to Canada,
Aotearoa/New Zealand (www.singaotearoa.net), and most
recently Australia, SING is a week-long workshop that aims to
train Indigenous students, scholars, community members, and
researchers with next-generation genomic and bioinformatics
analyses and build capacity for scientific research involving
Indigenous communities. SING operates internationally
through the expanding network of the SING Consortium
and has organized earlier this year the first international
conference on Indigenous genomics (103). Capacity building
in genomic science for Indigenous communities is also
being supported through programs and translational
activities associated with Silent Genomes and the Aotearoa
Variome (50).
CONCLUSION
Herein, we outline some challenges and barriers to rare
disease diagnosis in Indigenous people, and some examples
of initiatives raising awareness and advancing solutions to the
related challenges to diagnostic equity. Serving the unmet needs
of Indigenous people with undiagnosed rare diseases will require
a multifarious and internationally coordinated response that
is grounded in engagement, co-design, and trust. Ultimately,
improving Indigenous rare disease diagnosis will reduce inequity
and deliver discovery, innovation, and solutions that will
benefit all.
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